Pfizer's rejection of the mini-tender offer is likely to be viewed positively by shareholders, as it suggests that the company believes its stock is undervalued at the offer price. This could lead to increased confidence in Pfizer's stock, potentially stabilizing or increasing its price in the short term. However, since the offer is for a relatively small number of shares, the overall impact on the stock may be limited.